A Breakthrough in Treating Obstructive Sleep Apnoea
Biological Tendon Tether Technology (BTTT) - An imminent solution to a global health crisis affecting 1 billion people worldwide
1B
Adults affected worldwide
450M
Patients require intervention
€184B
Annual cost across the EU
30-60%
CPAP non-adherence rate
The BTTT Solution
How It Works
1. Surgical Implantation: A biological scaffold is implanted via a one-time surgical procedure
2. Natural Integration: The body grows a tendon-like structure, naturally integrating with the immune system
3. Permanent Solution: The result is a permanent anatomical correction that advances and anchors the tongue base
What Makes It Different
✓ Passive System: No external intervention needed unlike CPAP
✓ One-Time Treatment: No mechanical failure or degradation
✓ Addresses Root Cause: Prevents airway collapse during sleep
✓ Backed by Science: Cutting-edge tissue engineering with IP protection
Clinical Validation
✓ Patents granted in USA, China, UK, France, Germany, Spain, and South Africa
✓ Clinical trials underway with rigorous safety monitoring
✓ Animal trials demonstrated successful tendon formation
Development Milestones
✓ Completed: Animal Trials & Ethics Approval
Successful animal trials demonstrating safety and tendon formation. SAHPRA ethics approval obtained.
✓ Completed: Patent Protection
PCT patent application filed and granted in major global markets including USA and China.
✓ Completed: First Human Implant (May 2025)
Successful first human implantation marking a major milestone for the technology.
In Progress: Phase 1 Clinical Trial (30 patients)
Clinical validation underway with comprehensive safety and efficacy monitoring.
Next: Phase 2-3 Trials (120 patients)
Large-scale clinical validation to complete regulatory requirements.
Target: Market Ready
Regulatory approval, scaled production, and commercial launch in key markets.
Prof. Mogamat Rushdi Hendricks
Founder & CEO / Chief Medical Officer
Lead surgeon and inventor with 30+ years experience. PhD in Plastic Reconstructive and Maxillofacial Surgery. Fellow of the Royal Society of South Africa. Pioneered BTTT technology. Read more
Our Leadership Team
Francois Oosthuizen
Project Manager
Innovation translation specialist managing clinical operations and project coordination. Expert in medical device development.
Dr. Marike Smit
Technology Lead
Polymer scientist specializing in biomaterials and tissue engineering. Key contributor to BTTT device development.
Joel Du Toit
Production Manager
Oversees manufacturing processes, quality assurance, and supply chain operations for BTTT device production.
Strategic Partners
University of Cape Town
R&D partner and shareholder. Provides research facilities, intellectual property support, and clinical expertise through the Division of Surgery.
Stocks-Charles AB
Commercial operations partner leading market entry, business development, internationalization, and fundraising activities.
OSTA Biomedical
Regulatory partner providing quality management systems, regulatory compliance support, and certification processes.
Our Vision
To revolutionize the treatment of Obstructive Sleep Apnoea by providing a permanent, biological solution that addresses the root cause of airway collapse, transforming the lives of millions of people worldwide and establishing a new standard of care in sleep medicine.
Our Mission
Innovate
Develop cutting-edge tissue engineering solutions that provide permanent anatomical correction for OSA patients
Deliver
Make BTTT technology accessible to patients worldwide through strategic partnerships and scalable production
Transform
Improve quality of life for OSA sufferers through a one-time surgical treatment with lasting results
Our Values
Innovation
Pioneering biological solutions through cutting-edge tissue engineering and research excellence
Patient-Centered
Prioritizing patient well-being and quality of life in every decision we make
Excellence
Maintaining the highest standards in clinical validation, safety, and efficacy
Collaboration
Building strong partnerships with healthcare professionals, researchers, and institutions
Commercial Opportunity
$393M
Projected revenue in 5 years
705,000
Units/year addressable market
Need to updated numbers.
$1.1B
Projected gross profit in 8 years
10X
Investment opportunity within 8 years
Market Strategy
Distribution Model: Regional medical device distributors in key markets
Surgeon Training: Comprehensive certification program with regional training surgeons
Target: 2,350+ surgeons trained worldwide by year 5
Sales Channels: Certified surgical partners and established distribution networks
Production & Pricing
Current Unit Cost: Low cost with optimization potential
Production: Modular, scalable on-demand manufacturing
Inventory: Low financial risk with distributor deposits
Quality: ISO 13485 compliant manufacturing processes
Investment Highlights
✓ High-growth market with unmet medical need
✓ Strong patent protection in major markets
✓ Category-defining technology with scalable IP
✓ Clear path to regulatory approval and commercialization
Financial Projections (8-Year Timeline)
Add coloums of the 8 year timeline
Investor Registration
Join us in bringing a category-defining BioTech solution to market. Register your interest to learn more about our investment opportunity.
Investment Proposition
Deal Structure: 30% Equity Equivalent
Capital Raise: $11M for market entry phase
Use of Funds: Clinical trials completion, regulatory approvals, scaling production, surgeon training program, and commercial operations
Projected Returns: 10X investment opportunity within 8 years based on conservative market estimates
Market Opportunity: Access to $165B+ addressable market with limited competition in biological OSA solutions
For detailed investment materials, financial projections, and due diligence documentation, please contact:
info@apnea-cure.com